Study of FG-M108 plus FG-B901 for CLDN18.2-positive advanced tumors
Part of Cancer clinical trials.
This trial tests a combination of two experimental drugs for people with advanced cancer that has not responded to standard treatment. The drugs target a specific protein (CLDN18.2) found on some tumor cells. The goal is to see if the combination can shrink tumors or slow their growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have advanced cancer that has not responded to standard treatment or you cannot tolerate it.
- Your tumor tests positive for a marker called CLDN18.2 (a lab test will confirm).
- You are between 18 and 75 years old.
- You have at least one tumor that can be measured on scans.
- You are well enough to perform daily activities (ECOG score 0 or 1).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called LCB02A, which targets a protein called Claudin 18.2 found on some cancer cells. It is for people with advanced solid tumors that have not responded to standard treatments.
This trial tests a new drug, SIBP-A18, for people with advanced solid tumors that have not responded to standard treatments. It may be an option for those with certain cancers that have a protein called CLDN18.2.
This trial tests a new drug called FG-B901, either alone or with chemotherapy, for people with advanced solid tumors that haven't responded to standard treatment. The goal is to see if the drug can shrink tumors or slow their growth.
This Phase 1 study tests SG1906, a new investigational drug, in people with certain advanced solid tumors that test positive for CLDN18.2. The goal is to see whether the drug is safe and to learn how well it may work in shrinking tumors or controlling the disease.
This Phase 2 trial tests a combination anti-cancer medicine (LM-302) plus other anti-tumor treatments for advanced gastrointestinal cancers. It’s designed for people whose tumors test positive for CLDN18.2 and who have already tried standard first-line treatment but didn’t respond or couldn’t tolerate it.
This trial tests a new drug called NBL-028 in people with advanced solid tumors that have a specific protein (CLDN6). It is for those who have already tried standard treatments. The goal is to see how safe and effective the drug is.
Hear when a new Claudin 18.2 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.